Skip to main content
Top
Published in: Medical Oncology 7/2017

01-07-2017 | Original Paper

Neutralization of matrix metalloproteinase-9 potentially enhances oncolytic efficacy of tanapox virus for melanoma therapy

Authors: Tiantian Zhang, Yogesh R. Suryawanshi, Blair R. Szymczyna, Karim Essani

Published in: Medical Oncology | Issue 7/2017

Login to get access

Abstract

Matrix metalloproteinases (MMPs), which are involved in degradation of extracellular matrix, are critical regulators in tumor progression, metastasis and angiogenesis. Although induction of MMPs is frequently observed during the viral infection, the effect of MMPs on viral replication varies between viruses. MMP-9, for instance, is upregulated and promotes the replication of some viruses, such as herpes simplex virus, but inhibits the replication of others. Here, we report that infection with tanapox virus (TPV) promotes the expression of MMP-9 in the melanoma cells. In addition, we show that MMP-9 exerts an anti-viral effect on TPV replication and plays a protective role in TPV-infected melanoma cells in vitro. Moreover, the neutralization of MMP-9 in melanoma cells remarkably enhances the TPV infection and leads to a significant reduction in cell survival. In summary, this study contributes to understanding of the role played by MMP-9 in TPV infectivity and provides more insights for using TPV as cancer virotherapy in future studies. Since TPV has shown substantial oncolytic efficacy in promoting melanoma tumor regression in animal models, identifying mechanisms that suppress MMP-9 expression upon TPV infection can potentially improve its use as a melanoma virotherapy.
Literature
1.
go back to reference Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;7:572–6.PubMedPubMedCentral Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;7:572–6.PubMedPubMedCentral
2.
go back to reference Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med. 2011;364:2507–16.CrossRefPubMedPubMedCentral Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med. 2011;364:2507–16.CrossRefPubMedPubMedCentral
3.
go back to reference Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14:559–67.CrossRefPubMed Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14:559–67.CrossRefPubMed
5.
go back to reference Nazarian SH, Barrett JW, Stanford MM, Johnston JB, Essani K, McFadden G. Tropism of Tanapox virus infection in primary human cells. Virology. 2007;368:32–40.CrossRefPubMed Nazarian SH, Barrett JW, Stanford MM, Johnston JB, Essani K, McFadden G. Tropism of Tanapox virus infection in primary human cells. Virology. 2007;368:32–40.CrossRefPubMed
6.
go back to reference Jezek Z, Arita I, Szczeniowski M, Paluku KM, Ruti K, Nakano JH. Human tanapox in Zaire: clinical and epidemiological observations on cases confirmed by laboratory studies. Bull World Health Organ. 1985;63:1027–35.PubMedPubMedCentral Jezek Z, Arita I, Szczeniowski M, Paluku KM, Ruti K, Nakano JH. Human tanapox in Zaire: clinical and epidemiological observations on cases confirmed by laboratory studies. Bull World Health Organ. 1985;63:1027–35.PubMedPubMedCentral
7.
go back to reference Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, Cameron C, et al. Poxviruses and immune evasion. Annu Rev Immunol. 2003;21:377–423.CrossRefPubMed Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, Cameron C, et al. Poxviruses and immune evasion. Annu Rev Immunol. 2003;21:377–423.CrossRefPubMed
8.
go back to reference Conrad SJ, El-Aswad M, Kurban E, Jeng D, Tripp BC, Nutting C, et al. Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice. J Exp Clin Cancer Res. 2015;34:19.CrossRefPubMedPubMedCentral Conrad SJ, El-Aswad M, Kurban E, Jeng D, Tripp BC, Nutting C, et al. Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice. J Exp Clin Cancer Res. 2015;34:19.CrossRefPubMedPubMedCentral
9.
go back to reference Zhang T, Suryawanshi YR, Kordish DH, Woyczesczyk HM, Jeng D, Essani K. Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice. Virus Genes. 2017;53:52–62.CrossRefPubMed Zhang T, Suryawanshi YR, Kordish DH, Woyczesczyk HM, Jeng D, Essani K. Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice. Virus Genes. 2017;53:52–62.CrossRefPubMed
10.
go back to reference Jeng D, Ma Z, Barrett JW, McFadden G, Loeb JA, Essani K. The tanapoxvirus 15L protein is a virus-encoded neuregulin that promotes viral replication in human endothelial cells. J Virol. 2013;87:3018–26.CrossRefPubMedPubMedCentral Jeng D, Ma Z, Barrett JW, McFadden G, Loeb JA, Essani K. The tanapoxvirus 15L protein is a virus-encoded neuregulin that promotes viral replication in human endothelial cells. J Virol. 2013;87:3018–26.CrossRefPubMedPubMedCentral
11.
go back to reference Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol. 2000;115:337–44.CrossRefPubMed Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol. 2000;115:337–44.CrossRefPubMed
12.
go back to reference Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer. 2002;97:432–8.CrossRefPubMed Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer. 2002;97:432–8.CrossRefPubMed
13.
go back to reference Verma RP, Hansch C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem. 2007;15:2223–68.CrossRefPubMed Verma RP, Hansch C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem. 2007;15:2223–68.CrossRefPubMed
14.
go back to reference van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol. 1997;151:665–70.PubMedPubMedCentral van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol. 1997;151:665–70.PubMedPubMedCentral
15.
go back to reference Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, van Muijen GN. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol. 2000;191:245–56.CrossRefPubMed Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, van Muijen GN. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol. 2000;191:245–56.CrossRefPubMed
16.
go back to reference De Palma AM, Verbeken E, Van Aelst I, Van den Steen PE, Opdenakker G, Neyts J. Increased gelatinase B/matrix metalloproteinase 9 (MMP-9) activity in a murine model of acute coxsackievirus B4-induced pancreatitis. Virology. 2008;382:20–7.CrossRefPubMed De Palma AM, Verbeken E, Van Aelst I, Van den Steen PE, Opdenakker G, Neyts J. Increased gelatinase B/matrix metalloproteinase 9 (MMP-9) activity in a murine model of acute coxsackievirus B4-induced pancreatitis. Virology. 2008;382:20–7.CrossRefPubMed
17.
go back to reference MacDougall JR, Bani MR, Lin Y, Muschel RJ, Kerbel RS. ‘Proteolytic switching’: opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. Br J Cancer. 1999;80:504–12.CrossRefPubMedPubMedCentral MacDougall JR, Bani MR, Lin Y, Muschel RJ, Kerbel RS. ‘Proteolytic switching’: opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. Br J Cancer. 1999;80:504–12.CrossRefPubMedPubMedCentral
18.
19.
go back to reference Kong MY, Whitley RJ, Peng N, Oster R, Schoeb TR, Sullender W, et al. Matrix Metalloproteinase-9 Mediates RSV Infection in vitro and in vivo. Viruses. 2015;7:4230–53.CrossRefPubMedPubMedCentral Kong MY, Whitley RJ, Peng N, Oster R, Schoeb TR, Sullender W, et al. Matrix Metalloproteinase-9 Mediates RSV Infection in vitro and in vivo. Viruses. 2015;7:4230–53.CrossRefPubMedPubMedCentral
20.
go back to reference Yeo SJ, Kim SJ, Kim JH, Lee HJ, Kook YH. Influenza a virus infection modulates the expression of type IV collagenase in epithelial cells. Arch Virol. 1999;144:1361–70.CrossRefPubMed Yeo SJ, Kim SJ, Kim JH, Lee HJ, Kook YH. Influenza a virus infection modulates the expression of type IV collagenase in epithelial cells. Arch Virol. 1999;144:1361–70.CrossRefPubMed
21.
go back to reference Ichiyama T, Morishima T, Kajimoto M, Matsushige T, Matsubara T, Furukawa S. Matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in influenza-associated encephalopathy. Pediatr Infect Dis J. 2007;26:542–4.CrossRefPubMed Ichiyama T, Morishima T, Kajimoto M, Matsushige T, Matsubara T, Furukawa S. Matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in influenza-associated encephalopathy. Pediatr Infect Dis J. 2007;26:542–4.CrossRefPubMed
22.
go back to reference Chapel C, Camara V, Clayette P, Salvat S, Mabondzo A, Leblond V, et al. Modulations of 92 kDa gelatinase B and its inhibitors are associated with HIV-1 infection in human macrophage cultures. Biochem Biophys Res Commun. 1994;204:1272–8.CrossRefPubMed Chapel C, Camara V, Clayette P, Salvat S, Mabondzo A, Leblond V, et al. Modulations of 92 kDa gelatinase B and its inhibitors are associated with HIV-1 infection in human macrophage cultures. Biochem Biophys Res Commun. 1994;204:1272–8.CrossRefPubMed
23.
go back to reference Hong CS, Fellows W, Niranjan A, Alber S, Watkins S, Cohen JB, et al. Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther. 2010;17:1200–5.CrossRefPubMedPubMedCentral Hong CS, Fellows W, Niranjan A, Alber S, Watkins S, Cohen JB, et al. Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther. 2010;17:1200–5.CrossRefPubMedPubMedCentral
24.
go back to reference Dabo AJ, Cummins N, Eden E, Geraghty P. Matrix Metalloproteinase 9 exerts antiviral activity against respiratory syncytial virus. PLoS ONE. 2015;10:e0135970.CrossRefPubMedPubMedCentral Dabo AJ, Cummins N, Eden E, Geraghty P. Matrix Metalloproteinase 9 exerts antiviral activity against respiratory syncytial virus. PLoS ONE. 2015;10:e0135970.CrossRefPubMedPubMedCentral
25.
go back to reference Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques. 1997;23:1094–7.PubMed Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques. 1997;23:1094–7.PubMed
26.
go back to reference Rotte A, Martinka M, Li G. MMP2 expression is a prognostic marker for primary melanoma patients. Cell Oncol. 2012;35:207–16.CrossRef Rotte A, Martinka M, Li G. MMP2 expression is a prognostic marker for primary melanoma patients. Cell Oncol. 2012;35:207–16.CrossRef
27.
go back to reference Luplertlop N, Misse D, Bray D, Deleuze V, Gonzalez JP, Leardkamolkarn V, et al. Dengue-virus-infected dendritic cells trigger vascular leakage through metalloproteinase overproduction. EMBO Rep. 2006;7:1176–81.CrossRefPubMed Luplertlop N, Misse D, Bray D, Deleuze V, Gonzalez JP, Leardkamolkarn V, et al. Dengue-virus-infected dendritic cells trigger vascular leakage through metalloproteinase overproduction. EMBO Rep. 2006;7:1176–81.CrossRefPubMed
28.
go back to reference Straat K, de Klark R, Gredmark-Russ S, Eriksson P, Soderberg-Naucler C. Infection with human cytomegalovirus alters the MMP-9/TIMP-1 balance in human macrophages. J Virol. 2009;83:830–5.CrossRefPubMed Straat K, de Klark R, Gredmark-Russ S, Eriksson P, Soderberg-Naucler C. Infection with human cytomegalovirus alters the MMP-9/TIMP-1 balance in human macrophages. J Virol. 2009;83:830–5.CrossRefPubMed
29.
go back to reference Ellerbroek SM, Halbleib JM, Benavidez M, Warmka JK, Wattenberg EV, Stack MS, et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res. 2001;61:1855–61.PubMed Ellerbroek SM, Halbleib JM, Benavidez M, Warmka JK, Wattenberg EV, Stack MS, et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res. 2001;61:1855–61.PubMed
30.
go back to reference Yeo SJ, Yun YJ, Lyu MA, Woo SY, Woo ER, Kim SJ, et al. Respiratory syncytial virus infection induces matrix metalloproteinase-9 expression in epithelial cells. Arch Virol. 2002;147:229–42.CrossRefPubMed Yeo SJ, Yun YJ, Lyu MA, Woo SY, Woo ER, Kim SJ, et al. Respiratory syncytial virus infection induces matrix metalloproteinase-9 expression in epithelial cells. Arch Virol. 2002;147:229–42.CrossRefPubMed
31.
go back to reference Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–98.CrossRefPubMed Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–98.CrossRefPubMed
32.
go back to reference Shafren D, Quah M, Wong Y, Andtbacka RH, Kaufman HL, Au GG. Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model. J Immunother Cancer. 2014;2:125.CrossRef Shafren D, Quah M, Wong Y, Andtbacka RH, Kaufman HL, Au GG. Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model. J Immunother Cancer. 2014;2:125.CrossRef
33.
go back to reference Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, et al. Phase II trial of intravenous administration of Reolysin®(Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther. 2012;20:1998–2003.CrossRefPubMedCentral Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, et al. Phase II trial of intravenous administration of Reolysin®(Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther. 2012;20:1998–2003.CrossRefPubMedCentral
34.
go back to reference Garber K. China approves world’s first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006;98:298–300.CrossRefPubMed Garber K. China approves world’s first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006;98:298–300.CrossRefPubMed
35.
go back to reference Zhang T, Essani K. Tanapoxvirus lacking the 15L gene inhibits melanoma cell growth in vitro by inducing interferon-lambda1 release. Virus Genes. 2017;53(3):477–82.CrossRefPubMed Zhang T, Essani K. Tanapoxvirus lacking the 15L gene inhibits melanoma cell growth in vitro by inducing interferon-lambda1 release. Virus Genes. 2017;53(3):477–82.CrossRefPubMed
36.
go back to reference Zhang T, Kordish DH, Suryawanshi YR, Eversole RR, Kohler S, Mackenzie CD, et al. Oncolytic tanapoxvirus expressing interleukin-2 is capable of inducing the regression of human melanoma tumors in the absence of T cells. Curr Cancer Drug Targets. 2017; In press. Zhang T, Kordish DH, Suryawanshi YR, Eversole RR, Kohler S, Mackenzie CD, et al. Oncolytic tanapoxvirus expressing interleukin-2 is capable of inducing the regression of human melanoma tumors in the absence of T cells. Curr Cancer Drug Targets. 2017; In press.
37.
go back to reference Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 2001;61:577–81.PubMed Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 2001;61:577–81.PubMed
38.
go back to reference Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Gene Dev. 2000;14:163–76.PubMedPubMedCentral Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Gene Dev. 2000;14:163–76.PubMedPubMedCentral
39.
40.
go back to reference Bendrik C, Robertson J, Gauldie J, Dabrosin C. Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Res. 2008;68:3405–12.CrossRefPubMed Bendrik C, Robertson J, Gauldie J, Dabrosin C. Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Res. 2008;68:3405–12.CrossRefPubMed
41.
42.
go back to reference Kuriyama N, Kuriyama H, Julin CM, Lamborn K, Israel MA. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum Gene Ther. 2000;11:2219–30.CrossRefPubMed Kuriyama N, Kuriyama H, Julin CM, Lamborn K, Israel MA. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum Gene Ther. 2000;11:2219–30.CrossRefPubMed
43.
go back to reference Cheng J, Sauthoff H, Huang Y, Kutler DI, Bajwa S, Rom WN, et al. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther. 2007;15:1982–90.CrossRefPubMed Cheng J, Sauthoff H, Huang Y, Kutler DI, Bajwa S, Rom WN, et al. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther. 2007;15:1982–90.CrossRefPubMed
44.
go back to reference Hijova E. Matrix metalloproteinases: their biological functions and clinical implications. Bratisl Lek Listy. 2005;106:127–32.PubMed Hijova E. Matrix metalloproteinases: their biological functions and clinical implications. Bratisl Lek Listy. 2005;106:127–32.PubMed
45.
go back to reference Krstic J, Santibanez JF. Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells. Sci World J. 2014;2014:521754.CrossRef Krstic J, Santibanez JF. Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells. Sci World J. 2014;2014:521754.CrossRef
Metadata
Title
Neutralization of matrix metalloproteinase-9 potentially enhances oncolytic efficacy of tanapox virus for melanoma therapy
Authors
Tiantian Zhang
Yogesh R. Suryawanshi
Blair R. Szymczyna
Karim Essani
Publication date
01-07-2017
Publisher
Springer US
Published in
Medical Oncology / Issue 7/2017
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-017-0988-0

Other articles of this Issue 7/2017

Medical Oncology 7/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.